Nasdaq
$0.9792▲ 2.53%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.0MShares out 6.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
41- 5d agoPre-market26.10.20 13:15filedEFFECTOther#●●●
FibroBiologics, Inc.
FibroBiologics, Inc.'s registration statement (Form S-1) was declared effective by the SEC on October 19, 2026. This approval allows the company to proceed with the issuance and sale of the securities described in the filing.…more
$0.9792+2.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoPre-market26.10.20 13:15filedEFFECTOther
FibroBiologics, Inc.
FibroBiologics, Inc. received effectiveness approval from the SEC on October 19, 2026, for its registration statement. This authorization allows the company to proceed with the issuance and sale of securities as detailed in the filing.…more
$0.9792+2.53%vs prev closeView filingShare - 10.13After-hours26.10.14 05:16POS AMOther
FibroBiologics, Inc.
FibroBiologics has officially deregistered its Form S-1 registration statement, which was originally declared effective on January 14, 2025, covering the resale of 41,489,581 shares of common stock. The company filed this Post-Effective Amendment No. 1 to terminate the effectiveness of the registration statement and remove all unsold securities from registration.…more
$0.9792+2.53%vs prev closeView filingShare
40 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:34#●●●#●●●
FibroBiologics Announces Positive Preclinical Data for Degenerative Disc Disease Treatment…more
FibroBiologics reported that its FSdC spheroids demonstrated superior disc height preservation in a rabbit model of degenerative disc disease. The findings were presented at the 2026 North American Spine Society Annual Meeting, highlighting the potential of its fibroblast-based therapeutic approach.…more
$0.9792+2.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 21:35
●●●●●●●● ●●●●● ●●●●●●
FibroBiologics announced that IP Australia has issued a notice of acceptance for its patent regarding cellular blends for cartilage and disc regeneration. This development strengthens the company's intellectual property portfolio in fibroblast-based therapeutics.…more
$0.9792+2.53%vs prev closeShareBenzinga - 10.7Pre-market26.10.07 21:15
●●●●●●●● ●●●●● ●●●●●●
FibroBiologics has filed a patent for a cell-based platform designed to continuously release therapeutic peptides within the body as an alternative to GLP-1 injections. While the technology aims to address current treatment limitations, it remains in the early stages of development without proven clinical results.…more
$0.9792+2.53%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report